AC   CVCL_2180
DR   ChEMBL-Cells; CHEMBL3307428
DR   ChEMBL-Targets; CHEMBL614880
DR   Lonza; 60
DR   TOKU-E; 4090
DR   Wikidata; Q54950645
RX   PubMed=2066183;
RX   PubMed=11132152;
RX   PubMed=17982631;
CC   Characteristics: Deficient in antigen processing.
CC   Transformant: ChEBI; CHEBI:23994; Ethyl methanesulfonate (Methylsulfonic acid ethyl ester; MSEE).
CC   Transformant: NCBI_TaxID; 11938; Rauscher murine leukemia virus (R-MuLV).
CC   Breed/subspecies: C57BL/6.
DI   NCIt; C21604; Mouse leukemia
OX   NCBI_TaxID=10090; ! Mus musculus
HI   CVCL_J385 ! RMA
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 19-12-19; Version: 13
RX   PubMed=2066183; DOI=10.1002/ijc.2910470711;
RA   Ljunggren H.-G., Ohlen C., Hoglund P., Franksson L., Karre K.;
RT   "The RMA-S lymphoma mutant; consequences of a peptide loading defect
RT   on immunological recognition and graft rejection.";
RL   Int. J. Cancer 47 Suppl. 6:38-44(1991).
RX   PubMed=11132152; DOI=10.1007/s002510000254;
RA   Howell D., Levitt J.M., Foster P.A., Guenther M.M., Shawar S.M.,
RA   Rich R.R., Rodgers J.R.;
RT   "Heterogeneity of RMA-S cell line: derivatives of RMA-S cells lacking
RT   H2-Kb and H2-Db expression.";
RL   Immunogenetics 52:150-154(2000).
RX   PubMed=17982631; DOI=10.3892/or.18.6.1463;
RA   Komohara Y., Harada M., Ishihara Y., Suekane S., Noguchi M.,
RA   Yamada A., Matsuoka K., Itoh K.;
RT   "HLA-G as a target molecule in specific immunotherapy against renal
RT   cell carcinoma.";
RL   Oncol. Rep. 18:1463-1468(2007).